+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook to 2035

  • PDF Icon

    Report

  • 189 Pages
  • March 2023
  • Region: Global
  • Research Nester Pvt. Ltd
  • ID: 5786617
The global nonalcoholic steatohepatitis (NASH) diagnostics market is anticipated to grow with a CAGR of approximately 24.0% over the forecast period, i.e., 2023- 2035. The market's expansion can be driven by the rising prevalence of NAFLD, which includes both NAFL and NASH, which increases the demand for enhanced nonalcoholic steatohepatitis (NASH) diagnostic tools. In developed countries, NAFLD, which includes both NAFL and NASH, is the most common cause of abnormal liver enzymes. Furthermore, the patients dealing with NAFLD and NASH are mostly asymptomatic, which means they needs an advanced technologies for the diagnosis of the disorders and their treatment. The market is estimated to garner a revenue of near to USD 10,255.0 million by the end of 2035, up from a revenue of about USD 989.0 million in the year 2022.

The global nonalcoholic steatohepatitis (NASH) diagnostics market is segmented into numerous segments, which include segmentation by type, end-user, and by region. By type, the market is segmented into serum biomarkers, hepatic fibrosis biomarkers, oxidative stress biomarkers, apoptosis biomarkers and others. By the end of 2035, the serum biomarkers segment is anticipated to garner the largest revenue of around USD 3,200.0 million, up from a revenue of close to USD 297.0 million in the year 2022. The segment’s growth can be attributed to the serum indicators of liver activity that specifically target the synthesis and deterioration of collagen. Furthermore, the increasing adoption of serum biomarkers as a diagnostic tool for nonalcoholic steatohepatitis (NASH), along with the rising popularity among the key players is further expected to surge the growth of the segment in the market.

On the basis of region, the global nonalcoholic steatohepatitis (NASH) diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America, amongst the market in all the other regions, is anticipated to garner the largest revenue of more than USD 4,072.0 million by the end of 2035. Moreover, in the year 2022, the market in the region generated a revenue of over USD 399.0 million. The growth of the region can be contributed to the rising diseases such as non-alcoholic fatty liver diseases, followed by an increasing population that is obese, which in turn is projected to boost the market’s growth in the region. On the other hand, the market in the Asia Pacific region is predicted to view rapidest growth over the forecast period on the back of increasing population percentage, and growing older population that are anticipated to rise the growth of the market in the Asia Pacific region.

Some of the prominent industry leaders in the global nonalcoholic steatohepatitis (NASH) diagnostics market that are included in our report are Echosens, Prometheus Laboratories, GENFIT SA, Siemens Medical Solutions USA, Inc., BioPredictive S.A.S, Quest Diagnostics Incorporated., Meridian Bioscience, Inc., Laboratory Corporation of America Holdings, Bristol-Myers Squibb Company, ONE WAY LIVER, SL, and others.

Table of Contents

1. An Outline of the Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
1.1. Market Definition
1.2. Market Segmentation
1.3. Product Overview
2. Assumptions and Abbreviations
3. Research Methodology & Approach
3.1. Research Process
3.2. Primary Research
3.2.1. Diagnostics Providers
3.2.2. End-Users
3.3. Secondary Research
3.4. Market Size Estimation
4. Summary of the Report for Key Decision Makers
5. Forces of the Market Constituents
5.1. Drivers Impacting the Growth of the Market
5.2. Market Trends for Better Business Practices
6. Key Market Opportunities for Business Growth
6.1. Based on the Type
6.2. Based on the End-user
6.3. Based on the Geographical Presence
7. Major Roadblocks for the Market Growth
8. Decarbonization Strategy and Carbon Credit Benefits for Market Players
8.1 Global Government Decarbonization Plans/Goals by Each Country under 2015 Agreement Agreed by 200 Countries
8.2 Measures taken by Countries to Reduce Carbon Footprints
8.3 Carbon Credits and Subsidy Plans/Benefits Rolled out by the Government for Market Players
8.4 Effective Ways to Harness Carbon-Credits and Impact on Profit Margins
8.5 Demand Impact on the Companies Opting for Carbon Credits
9. Government Regulations: How They Would Aid Business?10. Industry Risk Analysis
11. Global Economic Outlook: Challenges for Global Recovery and its Impact on Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
11.1 Ukraine-Russia Crisis
11.2 Potential US Economic Slowdown
12 Technology Advancement in Nonalcoholic Steatohepatitis (NASH) Diagnostics Market
13 Industry Supply Chain Analysis
14 Analysis on Diagnostic Models
15 Analysis on Recent Development or Trends16 Analysis on Types of Imaging Biomarkers17 Competitive Positioning: Strategies to Differentiate a Company From its Competitors
18 Competitive Model: A Detailed Inside View for Investors
18.1 Market Share of Major Companies Profiled, 2022
18.2 Business Profiles of Key Enterprises
18.2.1 Echosens
18.2.2 Prometheus Laboratories
18.2.3 GENFIT SA
18.2.4 Siemens Medical Solutions USA, Inc.
18.2.5 BioPredictive S.A.S
18.2.6 Quest Diagnostics Incorporated.
18.2.7 Meridian Bioscience, Inc.
18.2.8 Laboratory Corporation of America Holdings
18.2.9 Bristol-Myers Squibb Company
18.2.10 One Way Liver, SL
18.2.11 Other Major Players

19.0 Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market 2022-2035
19.1 Market Overview
19.2 Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
19.3 Year-on-Year (Y-o-Y) Growth Trend Analysis
19.4 Global Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
19.4.1 By Type
19.4.1.1 Serums Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
19.4.1.2 Hepatic Fibrosis Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
19.4.1.3 Oxidative Stress Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
19.4.1.4 Apoptosis Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
19.4.1.5 Others, Market Value (USD Million) CAGR, 2022-2035F
19.4.2 By End User
19.4.2.1 Pharma & CRO Industry, Market Value (USD Million) CAGR, 2022-2035F
19.4.2.2 Hospitals, Market Value (USD Million) CAGR, 2022-2035F
19.4.2.3 Academic Research Institutes, Market Value (USD Million) CAGR, 2022-2035F
19.4.2.4 Others, Market Value (USD Million) CAGR, 2022-2035F
19.4.3 By Geography
19.4.3.1 Market Overview
19.4.3.2 Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
19.4.3.3 Year-on-Year (Y-o-Y) Growth Comparative Analysis
19.4.3.3.1 North America, Market Value (USD Million) CAGR, 2022-2035F
19.4.3.3.2 Europe, Market Value (USD Million) CAGR, 2022-2035F
19.4.3.3.3 Asia Pacific, Market Value (USD Million) CAGR, 2022-2035F
19.4.3.3.4 Latin America, Market Value (USD Million) CAGR, 2022-2035F
19.4.3.3.5 Middle East and Africa, Market Value (USD Million) CAGR, 2022-2035F

20.0 Cross Analysis of Type w.r.t. End-user (USD Million), 2022
21.0 North America Nonalcoholic Steatohepatitis (NASH) Diagnostics Demand Outlook & Projections, 2022-2035: A Comprehensive Study for Stakeholders
21.1 Market Overview
21.2 Analysis on Govt. Guidelines, Leading Companies and Other Factors in the region & Impact on Y-O-Y Revenue
21.3 Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
21.4 Year-on-Year (Y-o-Y) Growth Trend Analysis
21.5 North America Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
21.5.1 By Type
21.5.1.1 Serums Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
21.5.1.2 Hepatic Fibrosis Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
21.5.1.3 Oxidative Stress Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
21.5.1.4 Apoptosis Biomarkers, Market Value (USD Million) CAGR, 2022-2035F
21.5.1.5 Others, Market Value (USD Million) CAGR, 2022-2035F
21.5.2 By End User
21.5.2.1 Pharma & CRO Industry, 2022-2035F (USD Million)
21.5.2.2 Hospitals, 2022-2035 (USD Million)
21.5.2.3 Academic Research Institutes, 2022-2035F (USD Million)
21.5.2.4 Others, 2022-2035 (USD Million)
21.5.3 By Country
21.5.3.1 US, Market Value (USD Million) CAGR, 2022-2035F
21.5.3.2 Canada, Market Value (USD Million) CAGR, 2022-2035F
22. Europe Nonalcoholic Steatohepatitis (NASH) Diagnostics Demand Outlook & Projections, 2022 to 2035: A Comprehensive Study for Stakeholders
22.1 Market Overview
22.2 Analysis on Govt. Guidelines, Leading Companies and Other Factors in the region & Impact on Y-O-Y Revenue
22.3 Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
22.4 Year-on-Year (Y-o-Y) Growth Trend Analysis
22.5 Europe Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
22.5.1 By Type
22.5.2 By End User
22.5.3 By Country
22.5.3.1 UK, Market Value (USD Million) CAGR, 2022-2035F
22.5.3.2 Germany, Market Value (USD Million) CAGR, 2022-2035F
22.5.3.3 Italy, Market Value (USD Million) CAGR, 2022-2035F
22.5.3.4 France, Market Value (USD Million) CAGR, 2022-2035F
22.5.3.5 Spain, Market Value (USD Million) CAGR, 2022-2035F
22.5.3.6 Russia, Market Value (USD Million) CAGR, 2022-2035F
22.5.3.7 Netherlands, Market Value (USD Million) CAGR, 2022-2035F
23. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics Demand Outlook & Projections, 2022 to 2035: A Comprehensive Study for Stakeholders
23.1 Market Overview
23.2 Analysis on Govt. Guidelines, Leading Companies and Other Factors in the region & Impact on Y-O-Y Revenue
23.3 Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
23.4 Year-on-Year (Y-o-Y) Growth Trend Analysis
23.5 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
23.5.1 By Type
23.5.2 By End User
23.5.3 By Country
23.5.3.1 China, Market Value (USD Million) CAGR, 2022-2035F
23.5.3.2 India, Market Value (USD Million) CAGR, 2022-2035F
23.5.3.3 Japan, Market Value (USD Million) CAGR, 2022-2035F
23.5.3.4 Australia, Market Value (USD Million) CAGR, 2022-2035F
23.5.3.5 South Korea, Market Value (USD Million) CAGR, 2022-2035F
23.5.3.6 Singapore, Market Value (USD Million) CAGR, 2022-2035F
23.5.3.7 Rest of Asia Pacific, Market Value (USD Million) CAGR, 2022-2035F
24. Latin America Nonalcoholic Steatohepatitis (NASH) Diagnostics Demand Outlook & Projections, 2022 to 2035: A Comprehensive Study for Stakeholders
24.1 Market Overview
24.2 Analysis on Govt. Guidelines, Leading Companies and Other Factors in the region & Impact on Y-O-Y Revenue
24.3 Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
24.4 Year-on-Year (Y-o-Y) Growth Trend Analysis
24.5 Latin America Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
24.5.1 By Type
24.5.2 By End User
24.5.3 By Country
24.5.3.1 Brazil, Market Value (USD Million) CAGR, 2022-2035F
24.5.3.2 Argentina, Market Value (USD Million) CAGR, 2022-2035F
24.5.3.3 Mexico, Market Value (USD Million) CAGR, 2022-2035F
24.5.3.4 Rest of Latin America, Market Value (USD Million) CAGR, 2022-2035F
25. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Diagnostics Demand Outlook & Projections, 2022 to 2035: A Comprehensive Study for Stakeholders
25.1 Market Overview
25.2 Analysis on Govt. Guidelines, Leading Companies and Other Factors in the region & Impact on Y-O-Y Revenue
25.3 Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
25.4 Year-on-Year (Y-o-Y) Growth Trend Analysis
25.5 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Diagnostics Market Outlook & Projections, Opportunity Assessment by Segment, 2022-2035
25.5.1 By Type
25.5.2 By End User
25.5.3 Country
25.5.3.1 GCC North Africa, Market Value (USD Million) CAGR, 2022-2035F
25.5.3.2 Israel, Market Value (USD Million) CAGR, 2022-2035F
25.5.3.3 South Africa, Market Value (USD Million) CAGR, 2022-2035F
25.5.3.4 Rest of the Middle East and Africa, Market Value (USD Million) CAGR, 2022-2035F

Companies Mentioned

  • Echosens
  • Prometheus Laboratories
  • GENFIT SA
  • Siemens Medical Solutions USA Inc.
  • BioPredictive S.A.S
  • Quest Diagnostics Incorporated.
  • Meridian Bioscience Inc.
  • Laboratory Corporation of America Holdings
  • Bristol-Myers Squibb Company
  • ONE WAY LIVER
  • SL